Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP531039.RAqeLiRw_PreAMMihQPfXJNNlD-3JE2umuJ1v2vTvOE1Q130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP531039.RAqeLiRw_PreAMMihQPfXJNNlD-3JE2umuJ1v2vTvOE1Q130_assertion type Assertion NP531039.RAqeLiRw_PreAMMihQPfXJNNlD-3JE2umuJ1v2vTvOE1Q130_head.
- NP531039.RAqeLiRw_PreAMMihQPfXJNNlD-3JE2umuJ1v2vTvOE1Q130_assertion description "[Considering only those patients with cerebral toxoplasmosis from whom CSF was collected before or during the first week of antitoxoplasmic therapy, sensitivity rose to 50%.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP531039.RAqeLiRw_PreAMMihQPfXJNNlD-3JE2umuJ1v2vTvOE1Q130_provenance.
- NP531039.RAqeLiRw_PreAMMihQPfXJNNlD-3JE2umuJ1v2vTvOE1Q130_assertion evidence source_evidence_literature NP531039.RAqeLiRw_PreAMMihQPfXJNNlD-3JE2umuJ1v2vTvOE1Q130_provenance.
- NP531039.RAqeLiRw_PreAMMihQPfXJNNlD-3JE2umuJ1v2vTvOE1Q130_assertion SIO_000772 8958252 NP531039.RAqeLiRw_PreAMMihQPfXJNNlD-3JE2umuJ1v2vTvOE1Q130_provenance.
- NP531039.RAqeLiRw_PreAMMihQPfXJNNlD-3JE2umuJ1v2vTvOE1Q130_assertion wasDerivedFrom befree-20150227 NP531039.RAqeLiRw_PreAMMihQPfXJNNlD-3JE2umuJ1v2vTvOE1Q130_provenance.
- NP531039.RAqeLiRw_PreAMMihQPfXJNNlD-3JE2umuJ1v2vTvOE1Q130_assertion wasGeneratedBy ECO_0000203 NP531039.RAqeLiRw_PreAMMihQPfXJNNlD-3JE2umuJ1v2vTvOE1Q130_provenance.